Compound: doxazosin
SMILES: O=C(N1CCN(c2nc(N)c3cc(OC)c(cc3n2)OC)CC1)C4Oc5c(cccc5)OC4
InChIKey: RUZYUOTYCVRMRZ-UHFFFAOYSA-N
Synonyms: doxazosin, 74191-85-8, Doxazosine, Doxazosina, Doxazosinum, UK-33274, 1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin, UK 33274, 1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin, C02CA04, NW1291F1W8, CHEBI:4708, DTXSID7022964, Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)-, 2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine, (4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)METHANONE, (4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydro-1,4-benzodioxin-2-yl)methanone, ratio Doxazosin, ratio-Doxazosin, DoxaUro, Doxazosin Wolff, Novo Doxazosin, Apo Doxazosin, Gen Doxazosin, Doxa Puren, MTW Doxazosin, Neo, Carduran, [4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](2,3-dihydro-1,4-benzodioxin-2-yl)methanone, 2-(4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazin-1-yl)-6,7-dimethoxyquinazolin-4-amine, 2-(4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl)-6,7-dimethoxy-3,4-dihydroquinazolin-4-imine, 2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxy-3,4-dihydroquinazolin-4-imine, Doxazosin ratiopharm, Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]-, Ct, Doxazosin Von, Von Ct, Doxazosin, Doxazosina Ratiopharm, Ratiopharm, Doxazosina, RefChem:5778, Monohydrochloride, Doxazosin, DTXCID402964, UK33274, 616-059-6, Doxazosin (INN), C23H25N5O5, (RS)-2-{4-[(2,3-Dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine, [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone, (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanone, Doxazosine [French], Doxazosinum [Latin], DOXAZOSIN [INN], Doxazosina [Spanish], Doxazosin [INN:BAN], Methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](2,3-dihydro-1,4-benzodioxin-2-yl)-, Cardura XL (TN), supress, UNII-NW1291F1W8, METHANONE, (4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)-, 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine, CPD000097306, DOXAZOSIN [MI], Prestwick0_000858, Prestwick1_000858, Prestwick2_000858, Prestwick3_000858, DOXAZOSIN [VANDF], GlyTouCan:G08967HX, ChemDiv2_005017, CHEMBL707, EC 616-059-6, DOXAZOSIN [WHO-DD], (+/-)-DOXAZOSIN, 2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine, Lopac0_000474, Oprea1_259518, SCHEMBL34111, BSPBio_000875, SPBio_002796, BPBio1_000963, GTPL7170, orb1306007, SCHEMBL29641831, SCHEMBL29688095, BDBM86731, HMS1383E01, HMS2090C20, HMS3259N21, HMS3372L09, HMS3886J03, HMS5085L07, G08967HX, HY-B0098, ZCA19185, EBC-00685, MFCD00800482, NSC768144, NSC768145, s5782, AKOS001681453, AKOS017343634, CCG-118218, CS-1831, DB00590, NC00685, NSC-768144, NSC-768145, SDCCGSBI-0050459.P003, IDI1_003732, NCGC00018158-02, NCGC00018158-03, NCGC00018158-05, NCGC00018158-06, NCGC00018158-08, NCGC00018158-11, NCGC00018158-20, NCGC00089775-02, [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazine, 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine, AC-11062, AC-37660, AS-77104, SBI-0050459.P002, CAS_74191-85-8, DB-055848, UK 33,274, NS00000605, UK-3327427, EN300-53055, C06970, D07874, L000738, Q419939, BRD-A13188892-066-03-3, BRD-A13188892-066-13-2, BRD-A13188892-066-21-5, BRD-A13188892-066-22-3, 1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-(1,4-BENZODIOXAN-2-YLCARBONYL)PIPERAZINE, 137888-77-8
Theoretical properties:
molecular_formula: C23H25N5O5
molecular_weight: 451.5 g/mol
exact_mass: 451.18556891 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 9
rotatable_bond_count: 4
heavy_atom_count: 33
topological_polar_surface_area: 112 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 275-277
solubility: 0.8%
Descriptions:
{"pubchem": "Doxazosin is a member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure. It has a role as an antineoplastic agent, a vasodilator agent, an antihypertensive agent, an alpha-adrenergic antagonist and an antihyperplasia drug. It is a monocarboxylic acid amide, an aromatic amine, a member of quinazolines, a N-acylpiperazine, a N-arylpiperazine and a benzodioxine.", "chebi": "A member of the class of  quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An  antihypertensive agent, it is used in the treatment of high blood pressure.", "chembl": "DOXAZOSIN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Doxazosin, the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2023, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions."}